TABLE 2.

Summary of published tigecycline activity results^a

Organism source (no. tested/%)b	Tigecycline MIC (μg/ml)		% at MIC (μg/ml)		% by categoryc		Reference
	50%	90%	≤1	≤2	Susceptible	Resistant
Bacteremia (326/1.2)	0.5	2	74	95	94.5	0.9	23
Bacteremia (49/NA)	2	2	-	92	91.8	0.0	19
ICU (223/2.4)	1	2	65	93	93.3	0.9	22
Respiratory tract (143/4.5)	1	4	51	87	86.7	0.7	8
SSTI (61/1.2)	0.5	2	87	97	96.7	1.6	9

^aTested against 753 Acinetobacter sp. isolates among 51,619 strains reported from an international surveillance program (8, 9, 22, 23) and 49 additional bacteremias (19).

^bTotals for 753 strains, with the percentage of Acinetobacter sp. isolates among the species reported for each specimen source (8, 9, 22, 23). Reference 19 studied only bloodstream isolates. NA, not applicable; SSTI, skin and soft tissue infection.

^cCategories were defined using the U.S. FDA tigecycline package insert criteria for Enterobacteriaceae (≤2 μg/ml, susceptible) (Tygacil package insert [June 2005], Wyeth Pharmaceuticals Inc., Philadelphia, PA); resistance was defined as a tigecycline MIC at ≥8 μg/ml.